Work disability in psoriatic arthritis: A systematic review

Rheumatology

Volumn 51, Issue 2, 2012, Pages 275-283

  Tillett, William ^a   de Vries, Corinne ^a   McHugh, Neil J ^a  

^a University of Bath   (United Kingdom)

Author keywords

Absenteeism; Employment; Presenteeism; Psoriatic arthritis; Work disability

Indexed keywords

ACADEMIC ACHIEVEMENT; ARTICLE; DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SYSTEMATIC REVIEW; UNEMPLOYMENT; WORK DISABILITY;

ARTHRITIS, PSORIATIC; DISABILITY EVALUATION; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; WORK;

EID: 84856092780     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker216     Document Type: Article

References (38)

1. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-9.
2. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
3. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778-83.
4. Torre AJ RP, Arribas CJ, Ballina GJ, Riestra NJ, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Brit J Rheumatol 1991; 30:245-50.
5. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-7.
6. Escorpizo R, Bombardier C, Boonen A et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80.
7. Gladman DD, Mease PJ, Strand V et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70.
8. Boonen A, Severens JL. Rheumatic disease the socioeconomic perspective. ARC Topical Rev 2009;3:1-12.
9. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52: 3279-89.
10. Wallenius M, Skomsvoll JF, Koldingsnes W et al. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68: 685-9.
11. de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004;63:1362-7.
12. Altman DG. Systematic reviews of evaluations of prognostic variables. Br Med J 2001;323:224-8.
13. Fletcher D ST, Baker G, Street P, Hewlett S. I don't do sick leave; the work experience of people with inflammatory arthritis. Rheumatology 2010;49:i139-i40.
14. Marzo-Ortega H, Green MJ, Keenan AM, Wakefield RJ, Proudman S, Emery P. A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Rheum 2007;57:154-60.
15. Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:1570-7.
16. Gottlieb AB, Mease PJ, Mark Jackson J et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatol Treat 2006;17:279-87.
17. Christophers E, Barker JN, Griffiths CE et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010; 24:548-54.
18. Kaarela K, Lehtinen K, Luukkainen R. Work capacity of patients with inflammatory joint diseases. An eight-year follow-up study. Scand J Rheumatol 1987;16:403-6.
19. Kavanaugh A, Antoni C, Mease P et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9.
20. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683-91.
21. Zhu TY, Tam LS, Leung YY et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 37:1214-20.
22. Roberts ME, Wright V, Hill AG, Mehra AC. Psoriatic arthritis. Follow-up study. Ann Rheum Dis 1976;35: 206-12.
23. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32:721-8.
24. Gladman D, Sampalis JS, Martel MJ, Gooch KL, Wong RL, Guerette B. Impact of adalimumab on presenteeism for patients with psoriatic arthritis and reliability and validity of the work limitations questionnaire: results of ACCLAIM. J Rheumatol 2009;36:2595.
25. Gladman D, Psaradellis F, Martel MJ. Impact of adalimumab (humira®) on work productivity in patients with psoriatic arthritis: results from ACCLAIM. CRA Meeting. J Rheumatol 2009;6(Supp 2):2595.
26. Kavanaugh A, van der Heijde D, Gladman D. Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GOREVEAL study. Arthritis Rheum 2009;60:3861.
27. Sampalis JS, Gladman DD, Martel M-J, Gooch KL, Wong RL, Guerette B. Reliability and validity of the work limitations questionnaire in patients with psoriatic arthritis: results from ACCLAIM. Pharmacoepidemiol Drug Safety 2009;18:260.
28. Strober B, Guerin A, Mulani P, Gupta S. Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity. J Am Acad Dermatol 2009;60:AB181.
29. Brodszky V, Balint P, Geher P et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;12:PMS27.
30. Gladman D, Bombardier C, Thorne C et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting. J Rheumatol 2010; 36:1285-6.
31. Kumar SDP, Han J, Qureshi A. Getting to burden of disease: Willingness-to-pay (WTP) and dermatology life quality index (DLQI) in psoriasis and psoriatic arthritis. J Investig Dermatol 2010;130:S66.
32. Tang BCC, Freedman D, Wagner S, Piech CT. Clinical and economic burden in patients with psoriatic arthritis: results from the 2008 national health and wellness survey. J Manag Care Pharm 2009;15:1083-4087.
33. Meyer N, Paul C, Feneron D et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010;24:1075-82.
34. Kavanaugh A, Gladman D, Chattopadhyay C. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of the randomized, placebo-controlled go-reveal study. Rheumatology 2010;49:i56.
35. Beaton D, Bombardier C, Escorpizo R et al. Measuring worker productivity: Frameworks and measures. J Rheumatol 2009;36:2100-9.
36. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in ankylosing spondylitis. Rheumatology 2010;49:812-9.
37. Zhang W, Gignac MA, Beaton D, Tang K, Anis AH. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol 2010; 37:1805-14.
38. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. Br Med J 2001;323:42-6.